Germ cell tumors - testicular cancer

The testicle carcinoma, respectively the malignant germ cell tumor, is the most often tumor disease of men in the age of 20 to 35 years. There are two major groups that can be differentiated: so called seminoma and non-seminoma. This differentiation is made as a result of the tissue specimen analysis. In the case of seminoma the tumor marker Beta-hCG can be identified; Alpha-Feto-Protein (AFP) in the case of non-seminoma. For both tumors the lactate dehydrogenase (LDH) will be taken into consideration as a supplemental tumor marker. Depending on the level of tumor markers as well as on the histology chemotherapy with the drugs Cisplatin, Etoposid and Bleomycin will follow in 3 to 4 cycles. Usually these cycles will be applied in intervals of three weeks depending on the individual blood parameters. Due to this combination chemotherapy current cure rate of malignant testicular cancer is approximately 90%. Unfortunately, there is a low rate of cases where the first chemotherapy does not cause the hoped-for success and the patient will suffer a relapse. For those patients we are offering in our Department an intensive concept of chemotherapy under the so called P-ICE-study concept. Autologous blood stem cell support provides the opportunity to apply more intensive dose of chemotherapy. We have been applying those so called “high-dose-therapy” successfully for many years in cases of relapse of germ cell tumors.


 Based on our distinctly expertise in the field of germ cell tumors we are very pleased to support and advise you regarding possible treatment options.

For further information we would like to refer to the European Guideline (ESMO Clinical Practice Guideline), which was conceived in collaboration with Professor Dr. Jordan in 2010. This guideline was also published in the Annals of Oncology.


Prof. Dr. med.
Carsten Müller-Tidow

University Hospital Halle
Department of Inner Medicine IV
Hematology and Oncology
Ernst-Grube-Str. 40
D - 06120 Halle (Saale)
Phone: +49 345 557 2924
Fax: +49 345 557 2950
E-Mail: innere4©